Production (Stage)
Cryo-Cell International, Inc.
CCEL
$4.83
$0.030.63%
AMEX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.49% | 1.87% | 2.50% | 3.47% | 0.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.49% | 1.87% | 2.50% | 3.47% | 0.36% |
| Cost of Revenue | -3.96% | -71.59% | -1.41% | -5.52% | -0.05% |
| Gross Profit | 3.43% | 201.89% | 3.98% | 6.90% | 0.50% |
| SG&A Expenses | 4.74% | 10.39% | 9.07% | -0.44% | 14.17% |
| Depreciation & Amortization | 478.01% | -30.25% | -30.82% | -78.73% | -88.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.68% | -31.71% | 1.18% | -6.22% | 11.50% |
| Operating Income | 28.59% | 96.96% | 9.26% | 68.77% | -45.92% |
| Income Before Tax | -32.83% | 94.73% | 29.25% | 325.00% | -34.58% |
| Income Tax Expenses | 5.29% | 121.22% | -15.22% | 551.04% | -46.77% |
| Earnings from Continuing Operations | -49.14% | 83.36% | 54.53% | 196.74% | -27.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.14% | 83.36% | 54.53% | 196.74% | -27.46% |
| EBIT | 28.59% | 96.96% | 9.26% | 68.77% | -45.92% |
| EBITDA | 43.72% | 103.38% | 1.64% | 32.97% | -51.95% |
| EPS Basic | -47.92% | 82.91% | 58.83% | 204.91% | -25.83% |
| Normalized Basic EPS | 11.48% | 76.79% | -18.38% | 397.45% | -49.61% |
| EPS Diluted | -55.36% | 82.91% | 62.50% | 201.89% | -25.33% |
| Normalized Diluted EPS | 10.51% | 76.79% | -19.10% | 390.21% | -49.81% |
| Average Basic Shares Outstanding | -2.36% | -2.66% | -2.71% | -2.49% | -2.24% |
| Average Diluted Shares Outstanding | -1.50% | -2.66% | -2.02% | -1.20% | -1.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |